Brief: Maia Biotechnology Reports Preliminary Survival Data In Part A Of Thio-101 Phase 2 Trial For Non-Small Cell Lung Cancer
20/04/2023 13:01
April 20 (Reuters) - Maia Biotechnology Inc MAIA.A :
* MAIA BIOTECHNOLOGY REPORTS PRELIMINARY SURVIVAL DATA IN
PART A
OF THIO-101 PHASE 2 TRIAL FOR NON-SMALL CELL LUNG CANCER
* MAIA BIOTECHNOLOGY - FIRST 2 PATIENTS ENROLLED IN PART A
OF
STUDY CONTINUE TO BE ALIVE, ABOUT 10 AND 9 MONTHS RESPECTIVELY,
FROM TREATMENT INITIATION
Source text for Eikon: ID:nBw3S5LCta
Further company coverage: MAIA.A
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale